Bevacizumab with chemotherapy in advanced small bowel adenocarcinoma

Tarik Mahfoud; Mohamed Reda Khmamouche; Rachid Tanz; Hassan Errihani; Mohamed Ichou

Volume : VIII, Issue : VII, July - 2019

Bevacizumab with chemotherapy in advanced small bowel adenocarcinoma

Tarik Mahfoud, Mohamed Reda Khmamouche, Rachid Tanz, Hassan Errihani, Mohamed Ichou

Abstract :

Small bowel adenocarcinoma (SBA) is a rare disease; it represent less than 1% of gastrointestinal cancers. In metastatic setting, the standard treatment is chemotherapy using fluoropyramidine and platinum agents or irinotecan. Bevacizumab is a recombinant humanized monoclonal antibody that blocks vascular endothelial growth factor. It has proven survival benefits in multiple cancers. However, only a very few data are available about the efficacy of bevacizumab in SBA. We evaluate in this literature review its efficacy and its toxicity in SBA.